AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34543419
Drug: Relative weekly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Relative weekly change of progression >10% in running volume and progression in running pace
Trial: 34543419
Drug: Absolute weekly
RxNorm normalized name: Honey Absolute
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absolute weekly change of progression >5 km in running volume and progression in running pace
Trial: 34671676
Drug: Oral synthetic
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral synthetic vitamin E (400 IU/day) for eight weeks
Trial: 33874898
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg IV aminophylline (Group A1)
Trial: 33874898
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg IV aminophylline (Group A2)
Trial: 34244155
Drug: ω‐3‐FA (3.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐3‐FA (3.25 g/day combined EPA and DHA)
Trial: 34363762
Drug: Avelumab maintenance
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab maintenance (10 mg/kg intravenously every 2 weeks)
Trial: 34363762
Drug: Avelumab combination
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab combination (10 mg/kg intravenously every 3 weeks)
Trial: 34363762
Drug: Control (chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (chemotherapy followed by observation)
Trial: 35964041
Drug: LH-based flexible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LH-based flexible GnRH antagonist protocol
Trial: 35964041
Drug: Traditional flexible
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional flexible GnRH antagonist protocol
Trial: 33982405
Drug: Difelikefalin 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Difelikefalin 1.0 mcg/kg i.v.
Trial: 33982405
Drug: Difelikefalin 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Difelikefalin 5.0 mcg/kg i.v.
Trial: 32241693
Drug: Adjuvant targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant targeted therapy (TT)
Trial: 32241693
Drug: No adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant targeted therapy (TT)
Trial: 33113552
Drug: Nivolumab (anti-PD1)
RxNorm normalized name: Anti-PD1 / CTLA4 Bispecific Antibody XmAb20717
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab (anti-PD1) first-line therapy
Trial: 32917317
Drug: PPE 400
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PPE 400 mg per day
Trial: 36094202
Drug: Ensitrelvir 20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ensitrelvir 20, 70, 250, 500, 1,000, or 2,000 mg (part 1)
Trial: 36094202
Drug: Ensitrelvir 375/125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ensitrelvir 375/125 mg or 750/250 mg once daily for 5 days (part 2)
Trial: 36094202
Drug: Ensitrelvir 750/250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ensitrelvir 750/250 mg coadministered with midazolam
Trial: 35166054
Drug: SAR342434 insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR342434 insulin lispro
Trial: 35166054
Drug: Humalog insulin
RxNorm normalized name: insulin lispro Cartridge [Humalog]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humalog insulin lispro
Trial: 33518076
Drug: Conventional cages
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional cages (CC)
Trial: 33894327
Drug: Golexanolone (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golexanolone (10, 40 or 80 mg BID)
Trial: 33079152
Drug: 15-mg/d vericiguat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-mg/d vericiguat
Trial: 33079152
Drug: 10-mg/d vericiguat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mg/d vericiguat
Trial: 34653328
Drug: Liquid L-thyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid L-thyroxine (T4® drops)
Trial: 34653328
Drug: Tablets L-thyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets L-thyroxine (T4® tablets)
Trial: 32736555
Drug: Experiential Learning
RxNorm normalized name: Noxzema Clean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experiential Learning (EL) intervention, which included a lively presentation on oral health and role play in a simulated dental clinic.
Trial: 35078520
Drug: Pediatric Tuina
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric Tuina plus conventional treatment
Trial: 36114133
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (optimal nonpharmacologic therapy)
Trial: 34557956
Drug: Sham PBM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham PBM therapy
Trial: 32954647
Drug: Qishen Yiqi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qishen Yiqi dripping pills (QSYQ) for 6 months
Trial: 33907224
Drug: Paracetamol 1
RxNorm normalized name: Paracetamol 1 g oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1 g tablet formulation
Trial: 34488845
Drug: Low-cell dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-cell dose treatment group (n = 30)
Trial: 34488845
Drug: High-cell dose
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-cell dose treatment group (n = 30)
Trial: 35659571
Drug: Response-adjusted protocol
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Response-adjusted protocol (n=27) with tapering doses of prednisone over 8 weeks
Trial: 35659571
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care group (n=32) with standard protocol (60 mg/m2/24 hours for 6 weeks, followed by 40 mg/m2/48 hours for 4 weeks, followed by a slow taper for a total of 24 weeks)
Trial: 34273257
Drug: Whole tablets
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole tablets of apalutamide
Trial: 32103926
Drug: Budesonide/Glycopyrrolate/Formoterol Fumarate
RxNorm normalized name: budesonide/glycopyrrolate/formoterol fumarate 160 mcg-9 mcg-4.8 mcg/actuation INHALATION HFA AEROSOL WITH ADAPTER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/Glycopyrrolate/Formoterol Fumarate (BUD/GLY/FORM) triple therapy
Trial: 32103926
Drug: Budesonide/Formoterol Fumarate
RxNorm normalized name: budesonide/formoterol fumarate 80/4.5 MCG/INHAL Metered Dose Inhaler, 60 Actuations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/Formoterol Fumarate (BUD/FORM) dual therapy
Trial: 32103926
Drug: BUD/GLY/FORM triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUD/GLY/FORM triple therapy
Trial: 32393320
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care including home exercise (UCHE) plus spa therapy (18 days of mud packs, underwater massages, showers and water exercises under medical supervision)
Trial: 32393320
Drug: UCHE plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UCHE plus spa therapy
Trial: 34785236
Drug: Aspirin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (75 mg, once daily)
Trial: 33242515
Drug: Adherence to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence to prescribed medications
Trial: 32762226
Drug: Hemocoagulase treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemocoagulase treatment in patients with low coagulation index (CI)
Trial: 32897569
Drug: Rituximab (RTX)
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab (RTX) 1 g intravenous initially, then every 6 months for 12 months
Trial: 32897569
Drug: Glatiramer acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glatiramer acetate (GA) 40 mg subcutaneously 3 times/week for 12 months
Trial: 32410586
Drug: Perceived health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perceived health benefits of treatment for perinatal depression
Trial: 32826784
Drug: Yoga intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yoga intervention (2× weekly, 60-minute sessions for 12 weeks)
Trial: 34657138
Drug: AGMG0201 (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGMG0201 (active study drug)
Trial: 34657138
Drug: AGMG0201 (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGMG0201 (high-dose group)
Trial: 34657138
Drug: AGMG0201 (low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGMG0201 (low-dose group)
Trial: 34062976
Drug: Aguamiel-based beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aguamiel-based beverage fermented with Lactobacillus plantarum, Lactobacillus paracasei and Lactobacillus brevis (100 mL, 3 × 10^8 cfu/mL) for 8 weeks
Trial: 32381495
Drug: Video-observed therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video-observed therapy (VOT)
Trial: 32362132
Drug: HiBalance intervention
RxNorm normalized name: Rebalance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HiBalance intervention (10-week, two times weekly progressive balance training led by physical therapists)
Trial: 35623183
Drug: High-dose inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose inhaled nitric oxide (iNO) at 250 ppm for 30 minutes
Trial: 32854536
Drug: Sequential afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sequential afatinib followed by osimertinib
Trial: 33995600
Drug: Apatinib 500
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib 500 mg once daily
Trial: 35184413
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of apatinib and melittin
Trial: 35050320
Drug: Pembrolizumab (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (2 mg/kg or 10 mg/kg every 2 or 3 weeks)
Trial: 35368773
Drug: Tongdu Bushen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongdu Bushen acupuncture, intradermal acupuncture, and moxibustion integrated therapy combined with core muscle training program (CMT)
Trial: 36177926
Drug: Xiaoqinglong Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiaoqinglong Decoction (1 000 mg/L)
Trial: 36177926
Drug: Qingqi Huatan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingqi Huatan Pill (1 000 mg/L)
Trial: 36177926
Drug: PDTC (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDTC (100 μmol/L)
Trial: 33759250
Drug: Emodepside as
RxNorm normalized name: Emodepside
DrugBank: Emodepside (DB11403)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emodepside as LSF, single oral administration of 20 mg
Trial: 33759250
Drug: Emodepside as
RxNorm normalized name: Emodepside
DrugBank: Emodepside (DB11403)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emodepside as LSF, multiple oral administration over 10 days at 5 mg once daily and 10 mg once daily and 10 mg twice daily
Trial: 33759250
Drug: Emodepside as
RxNorm normalized name: Emodepside
DrugBank: Emodepside (DB11403)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emodepside as IR tablet, 5 or 20 mg
Trial: 33759250
Drug: Emodepside as
RxNorm normalized name: Emodepside
DrugBank: Emodepside (DB11403)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emodepside as LSF, doses from 1 to 40 mg
Trial: 32201234
Drug: Durvalumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (10 mg/kg every 2 weeks for up to 12 months)
Trial: 32201234
Drug: Durvalumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab + Tremelimumab (12 weeks durvalumab 20 mg/kg + tremelimumab 1 mg/kg q4w then 34 weeks durvalumab 10 mg/kg q2w)
Trial: 33289149
Drug: Postoperative decrease
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative decrease of albumin (ΔAlb) calculated on postoperative day 1, with a cut-off established at 11 g/L.
Trial: 36344108
Drug: IVC and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVC and lung ultrasound-guided decongestion therapy
Trial: 36344108
Drug: Clinical-guided decongestion
RxNorm normalized name: Qlearquil Nasal Decongestant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical-guided decongestion therapy
Trial: 33928857
Drug: Corticosteroid Injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid Injection (CI)
Trial: 34637505
Drug: High-protein milk-cereal
RxNorm normalized name: milk protein concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein milk-cereal mix (5.6 g protein, PER: 18%, 1.68 g from milk source)
Trial: 34637505
Drug: Modest-protein milk-cereal
RxNorm normalized name: milk protein concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modest-protein milk-cereal mix (2.5 g protein, PER: 8%; 0.75 g from milk source)
Trial: 32390309
Drug: 5% Benzoyl
RxNorm normalized name: BENZOYL PEROXIDE 2.5 g in 100 mL TOPICAL SOAP [Benzoyl Acne Wash -2.5% Benzoyl Peroxide]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% Benzoyl Peroxide (BPO), twice a day
Trial: 32390309
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 5% BPO + 3% Erythromycin, twice a day
Trial: 32390309
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 4% Niacinamide + 1% Gallic Acid + 1% Lauric Acid, twice a day
Trial: 36376310
Drug: Third dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third dose of CoronaVac at a 10-month interval (cohort 1)
Trial: 36376310
Drug: Third dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third dose of CoronaVac at a 12-month interval (cohort 2)
Trial: 35854358
Drug: 1-h music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-h music listening sessions twice daily through noise-canceling headphones
Trial: 35854358
Drug: 1-h sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-h sessions of a silence track twice daily through noise-canceling headphones
Trial: 35483010
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy followed by chemoradiotherapy (INCT‐CRT)
Trial: 35483010
Drug: Chemoradiotherapy followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy followed by consolidation chemotherapy (CRT‐CNCT)
Trial: 34185584
Drug: Eplerenone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone treatment
Trial: 35684021
Drug: RiaGev (Nicotinamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RiaGev (Nicotinamide and D-Ribose) 1520 mg twice daily for 7 days
Trial: 33620439
Drug: ≥50% of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ≥50% of the target β-blocker dose
Trial: 33620439
Drug: <50% of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: <50% of the target β-blocker dose
Trial: 32094049
Drug: Gentamicin implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin implant
Trial: 33239152
Drug: Inhaled control
RxNorm normalized name: Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled control medication (ICM)
Trial: 33239152
Drug: Short-acting beta-agonists
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting beta-agonists (SABA)
Trial: 33627253
Drug: Low serum
RxNorm normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low serum MBL (≤100 μg/L)
Trial: 32690640
Drug: rhu-pGSN single-dose
RxNorm normalized name: Rhu-pGSN
DrugBank: Recombinant human plasma gelsolin (DB15746)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhu-pGSN single-dose at 6 mg/kg
Trial: 32690640
Drug: rhu-pGSN multidose
RxNorm normalized name: Rhu-pGSN
DrugBank: Recombinant human plasma gelsolin (DB15746)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhu-pGSN multidose at 6, 12, or 24 mg/kg for 3 consecutive days
Trial: 32690640
Drug: Placebo single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo single-dose
Trial: 35839439
Drug: Combination cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination cognitive behavioral therapy and medication management algorithm
Trial: 35839439
Drug: Enhanced standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced standard of care (psychotherapy and medication management)
Trial: 34510174
Drug: High-spice diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-spice diet (HSD) 6.6 g/d/2100 kcal
Trial: 34510174
Drug: Moderate-spice diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-spice diet (MSD) 3.3 g/d/2100 kcal
Trial: 34510174
Drug: Low-spice diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-spice diet (LSD) 0.5 g/d/2100 kcal
Trial: 36075583
Drug: Reminiscence therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reminiscence therapy (RT) using digital material or storytelling for 4 weeks
Trial: 32385554
Drug: 4% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% chlorhexidine solution (CHG)
Trial: 34114501
Drug: Bioabsorbable bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioabsorbable bone hemostatic agent (BBHA)
Trial: 34015041
Drug: 2-day levofloxacin
RxNorm normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-day levofloxacin treatment
Trial: 34015041
Drug: CRP-guided levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CRP-guided levofloxacin treatment
Trial: 33074327
Drug: Bimagrumab 700
RxNorm normalized name: Bimagrumab
DrugBank: Bimagrumab (DB12584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimagrumab 700 mg monthly for 6 months
Trial: 32872052
Drug: Conventional low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Conventional low-dose spiral CT scan
Trial: 35758442
Drug: Dual trigger
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual trigger using gonadotropin releasing hormone agonist with human chorionic gonadotropin (hCG)
Trial: 34348576
Drug: Vagus nerve
RxNorm normalized name: SUS SCROFA VAGUS NERVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vagus nerve stimulation (VNS) as an adjunct to anti-seizure medications (ASMs)
Trial: 34348576
Drug: Anti-seizure medications
RxNorm normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-seizure medications (ASMs) only
Trial: 36116461
Drug: V116-1 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V116-1 (2 μg per pneumococcal polysaccharide [PnP] per 0·5 mL)
Trial: 36116461
Drug: V116-2 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V116-2 (4 μg per PnP per 1·0 mL)
Trial: 36116461
Drug: PPSV23 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPSV23 (25 μg per PnP per 0·5 mL)
Trial: 36116461
Drug: V116 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V116 (4 μg per PnP per 1·0 mL)
Trial: 34958620
Drug: Oxytocin plus
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin plus misoprostol (400 µg sublingual)
Trial: 33350222
Drug: Flunarizine combined
RxNorm normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine combined with Tongtian Oral Liquid
Trial: 33350222
Drug: Flunarizine combined
RxNorm normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine combined with Zhengtian Pills
Trial: 33350222
Drug: Flunarizine combined
RxNorm normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine combined with Toutongning Capsules
Trial: 33350222
Drug: Flunarizine combined
RxNorm normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine combined with Tianshu Capsules
Trial: 33350222
Drug: Flunarizine combined
RxNorm normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine combined with Xuefu Zhuyu Capsules
Trial: 33350222
Drug: Flunarizine combined
RxNorm normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine combined with Danzhen Toutong Capsules
Trial: 33350222
Drug: Flunarizine combined
RxNorm normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine combined with Songling Xuemaikang Capsules